Autoimmune polyendocrine syndrome primary prevention: Difference between revisions
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Primary Prevention== | ==Primary Prevention== | ||
Revision as of 13:23, 28 September 2017
|
Autoimmune polyendocrine syndrome Microchapters |
|
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune polyendocrine syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome primary prevention |
|
Autoimmune polyendocrine syndrome primary prevention in the news |
|
Blogs on Autoimmune polyendocrine syndrome primary prevention |
|
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
|
Risk calculators and risk factors for Autoimmune polyendocrine syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Primary Prevention
Effective measures for the primary prevention of autoimmune polyendocrine syndrome (APS) include:
- Patient education: Autoimmune polyendocrine syndrome may be inherited in autosomal recessive (APS type 1), autosomal dominant (APS type 2) or X linked fashion (APS type 3) and therefore educating relatives about presence of APS in family is necessary.
- Screening should be done for first degree relatives of patients with APS for auto-antibodies against 21- hydroxylase, 17-hydroxylase, thyroid peroxidase, parietal cell, anti-intrinsic factor and islet cell antibodies.
- Currently, there is not enough evidence to define optimal intervals for testing but data suggests that autoantibodies can develop at any age. Hence, we rescreen patients for autoantibodies even if their initial autoantibody tests are negative. Celiac disease, for instance, is usually asymptomatic and only detected after screening for transglutaminase autoantibodies.